GAN Competitors

Cardlytics (NASDAQ:CDLX) and GAN (NASDAQ:GAN) are both business services companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Institutional and Insider Ownership

97.0% of Cardlytics shares are held by institutional investors. Comparatively, 26.1% of GAN shares are held by institutional investors. 6.5% of Cardlytics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cardlytics and GAN's top-line revenue, earnings per share and valuation.

GAN has lower revenue, but higher earnings than Cardlytics.

Analyst Ratings

This is a summary of recent recommendations for Cardlytics and GAN, as provided by MarketBeat.com.

Cardlytics currently has a consensus price target of $77.1667, indicating a potential downside of 44.93%. GAN has a consensus price target of $29.25, indicating a potential upside of 6.56%. Given GAN's stronger consensus rating and higher probable upside, analysts plainly believe GAN is more favorable than Cardlytics.

Profitability

This table compares Cardlytics and GAN's net margins, return on equity and return on assets.

Summary

GAN beats Cardlytics on 7 of the 11 factors compared between the two stocks.

Yalla Group (NYSE:YALA) and GAN (NASDAQ:GAN) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Yalla Group and GAN, as reported by MarketBeat.com.

GAN has a consensus target price of $29.25, suggesting a potential upside of 6.56%. Given GAN's stronger consensus rating and higher probable upside, analysts plainly believe GAN is more favorable than Yalla Group.

Valuation and Earnings

This table compares Yalla Group and GAN's top-line revenue, earnings per share (EPS) and valuation.

GAN has higher revenue and earnings than Yalla Group.

Profitability

This table compares Yalla Group and GAN's net margins, return on equity and return on assets.

Insider and Institutional Ownership

26.1% of GAN shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

GAN beats Yalla Group on 7 of the 8 factors compared between the two stocks.

Pluralsight (NASDAQ:PS) and GAN (NASDAQ:GAN) are both business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares Pluralsight and GAN's gross revenue, earnings per share and valuation.

GAN has lower revenue, but higher earnings than Pluralsight.

Profitability

This table compares Pluralsight and GAN's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pluralsight and GAN, as reported by MarketBeat.com.

Pluralsight presently has a consensus target price of $21.23, indicating a potential upside of 1.05%. GAN has a consensus target price of $29.25, indicating a potential upside of 6.56%. Given GAN's stronger consensus rating and higher possible upside, analysts plainly believe GAN is more favorable than Pluralsight.

Institutional and Insider Ownership

80.5% of Pluralsight shares are owned by institutional investors. Comparatively, 26.1% of GAN shares are owned by institutional investors. 21.8% of Pluralsight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GAN beats Pluralsight on 8 of the 11 factors compared between the two stocks.

SVMK (NASDAQ:SVMK) and GAN (NASDAQ:GAN) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Insider & Institutional Ownership

77.5% of SVMK shares are owned by institutional investors. Comparatively, 26.1% of GAN shares are owned by institutional investors. 18.7% of SVMK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for SVMK and GAN, as provided by MarketBeat.com.

SVMK presently has a consensus price target of $27.5714, indicating a potential upside of 39.96%. GAN has a consensus price target of $29.25, indicating a potential upside of 6.56%. Given SVMK's higher possible upside, equities analysts clearly believe SVMK is more favorable than GAN.

Profitability

This table compares SVMK and GAN's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares SVMK and GAN's gross revenue, earnings per share (EPS) and valuation.

GAN has lower revenue, but higher earnings than SVMK.

Summary

GAN beats SVMK on 6 of the 11 factors compared between the two stocks.

GAN (NASDAQ:GAN) and Health Catalyst (NASDAQ:HCAT) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for GAN and Health Catalyst, as provided by MarketBeat.com.

GAN currently has a consensus price target of $29.25, indicating a potential upside of 6.56%. Health Catalyst has a consensus price target of $42.5385, indicating a potential downside of 11.69%. Given GAN's higher possible upside, equities analysts plainly believe GAN is more favorable than Health Catalyst.

Earnings and Valuation

This table compares GAN and Health Catalyst's revenue, earnings per share (EPS) and valuation.

GAN has higher earnings, but lower revenue than Health Catalyst.

Profitability

This table compares GAN and Health Catalyst's net margins, return on equity and return on assets.

Institutional and Insider Ownership

26.1% of GAN shares are owned by institutional investors. Comparatively, 94.2% of Health Catalyst shares are owned by institutional investors. 22.1% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GAN (NASDAQ:GAN) and Eventbrite (NYSE:EB) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

26.1% of GAN shares are held by institutional investors. Comparatively, 67.2% of Eventbrite shares are held by institutional investors. 16.8% of Eventbrite shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares GAN and Eventbrite's gross revenue, earnings per share and valuation.

GAN has higher earnings, but lower revenue than Eventbrite.

Profitability

This table compares GAN and Eventbrite's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GAN and Eventbrite, as provided by MarketBeat.com.

GAN currently has a consensus price target of $29.25, suggesting a potential upside of 6.56%. Eventbrite has a consensus price target of $12.80, suggesting a potential downside of 38.70%. Given GAN's stronger consensus rating and higher probable upside, research analysts clearly believe GAN is more favorable than Eventbrite.

Summary

GAN beats Eventbrite on 8 of the 11 factors compared between the two stocks.